These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21278561)

  • 21. Neuroendocrine liver metastases.
    Reddy SK; Clary BM
    Surg Clin North Am; 2010 Aug; 90(4):853-61. PubMed ID: 20637952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of advanced neuroendocrine tumors with hepatic metastasis.
    Khasraw M; Gill A; Harrington T; Pavlakis N; Modlin I
    J Clin Gastroenterol; 2009 Oct; 43(9):838-47. PubMed ID: 19654558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. General selection criteria of patients for radioembolization of liver tumors: an international working group report.
    Coldwell D; Sangro B; Wasan H; Salem R; Kennedy A
    Am J Clin Oncol; 2011 Jun; 34(3):337-41. PubMed ID: 20921882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
    Strosberg JR; Choi J; Cantor AB; Kvols LK
    Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
    Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
    Cancer; 2018 May; 124(9):1992-2000. PubMed ID: 29451701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases.
    Wasan H; Kennedy A; Coldwell D; Sangro B; Salem R
    Am J Clin Oncol; 2012 Jun; 35(3):293-301. PubMed ID: 21278562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques.
    Atwell TD; Charboneau JW; Que FG; Rubin J; Lewis BD; Nagorney DM; Callstrom MR; Farrell MA; Pitot HC; Hobday TJ
    Cardiovasc Intervent Radiol; 2005; 28(4):409-21. PubMed ID: 16041556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
    Chambers AJ; Pasieka JL; Dixon E; Rorstad O
    Surgery; 2008 Oct; 144(4):645-51; discussion 651-3. PubMed ID: 18847650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic neuroendocrine metastases: does intervention alter outcomes?
    Chamberlain RS; Canes D; Brown KT; Saltz L; Jarnagin W; Fong Y; Blumgart LH
    J Am Coll Surg; 2000 Apr; 190(4):432-45. PubMed ID: 10757381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioembolization in the treatment of neuroendocrine tumors of the pancreas.
    John PK; Saif MW
    JOP; 2014 Jul; 15(4):332-4. PubMed ID: 25076336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of pancreatic neuroendocrine tumors.
    Dickson PV; Behrman SW
    Surg Clin North Am; 2013 Jun; 93(3):675-91. PubMed ID: 23632152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases.
    Cao CQ; Yan TD; Bester L; Liauw W; Morris DL
    Br J Surg; 2010 Apr; 97(4):537-43. PubMed ID: 20205229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of well-differentiated gastrointestinal neuroendocrine tumors metastatic to the liver.
    Wang SC; Fidelman N; Nakakura EK
    Semin Oncol; 2013 Feb; 40(1):69-74. PubMed ID: 23391114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma.
    D'Avola D; Lñarrairaegui M; Bilbao JI; Martinez-Cuesta A; Alegre F; Herrero JI; Quiroga J; Prieto J; Sangro B
    Hepatogastroenterology; 2009; 56(96):1683-8. PubMed ID: 20214218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis.
    Pollock RF; Brennan VK; Peters R; Paprottka PM
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):997-1009. PubMed ID: 32930618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver-directed therapies for metastatic neuroendocrine tumors.
    Garrot C; Stuart K
    Hematol Oncol Clin North Am; 2007 Jun; 21(3):545-60; ix-x. PubMed ID: 17548039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of hepatic metastases of neuroendocrine malignancies: a 10-year experience.
    Dejong CH; Parks RW; Currie E; Piris J; Redhead DN; Garden OJ
    J R Coll Surg Edinb; 2002 Apr; 47(2):495-9. PubMed ID: 12018694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases - a systematic review.
    Yang TX; Chua TC; Morris DL
    Surg Oncol; 2012 Dec; 21(4):299-308. PubMed ID: 22846894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres.
    Evans KA; Richardson MG; Pavlakis N; Morris DL; Liauw W; Bester L
    J Vasc Interv Radiol; 2010 Oct; 21(10):1521-6. PubMed ID: 20813542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioembolization in patients with hepatic metastases from breast cancer.
    Jakobs TF; Hoffmann RT; Fischer T; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Reiser MF; Helmberger TK
    J Vasc Interv Radiol; 2008 May; 19(5):683-90. PubMed ID: 18440456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.